Myovant Sciences and Accord Healthcare, Ltd. enter into exclusive license agreement to commercialize Orgovyx for advanced hormone-sensitive prostate cancer in Europe.
Myovant Sciences and Accord Healthcare, Ltd. announced that they have entered into an exclusive license agreement for Accord to commercialize relugolix for the treatment of advanced hormone-sensitive prostate cancer under the trade name Orgovyx (relugolix, 120 mg) in the European Economic Area, United Kingdom, Switzerland and Turkey, with the right of first negotiation if Myovant decides to enter into licensing arrangements in countries in the Middle East, Africa and India.